Biogen Secures $250M Funding to Propel Global Biotech Innovation

Biogen, a global leader in biotechnology since its founding in 1978, is thrilled to announce the successful raising of $250,000,000 in its latest funding round.

This remarkable milestone not only underscores the unwavering confidence of our investors in our pioneering approach to innovative science but also fuels our mission to transform the lives of patients worldwide.

With deep expertise in human biology and a commitment to leveraging diverse treatment modalities, Biogen continues to set the benchmark for first-in-class therapies that deliver superior patient outcomes.

The new funds will be strategically deployed to accelerate research and development efforts, enhance our state-of-the-art manufacturing capabilities, and expand our global clinical programs.

This investment will empower our team of approximately 7,000 talented professionals, based at our headquarters in Cambridge, Massachusetts, and our international centers in Baar, Switzerland, North Carolina, and Solothurn, Switzerland.

By amplifying our efforts across research, manufacturing, and distribution, we are poised to sustain long-term growth, ensuring that breakthrough treatments reach patients faster and more efficiently across 30 direct affiliate markets and over 50 additional territories through our trusted network of distribution partners.

As we take bold, calculated risks to drive forward the future of healthcare, our commitment to delivering value for shareholders and our communities remains steadfast.

We invite you to follow our journey and learn more about our groundbreaking initiatives by visiting www.biogen.com, and joining us on LinkedIn, Facebook, X, and YouTube.

This funding achievement marks a significant chapter in our history as we continue to shape a healthier tomorrow for millions around the world.